Clearmind Medici SEC Filings

Clearmind Medicine Inc. reports completion of dosing for all 24 participants in Cohorts 1–4 of Part A of its FDA-regulated Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder. Healthy volunteers received escalating dose levels of the company’s proprietary, non-hallucinogenic drug candidate.

The multicenter trial is being conducted under FDA oversight as a randomized, double-blind, placebo-controlled study at leading sites including Yale and Johns Hopkins. Interim results from the first three cohorts continue to show a strong safety profile, supporting further advancement of the program. Clearmind also highlights an intellectual property portfolio of nineteen patent families with 31 granted patents.

Clearmind Medicine Inc. is registering the resale of up to 21,875 common shares issuable upon exercise of January 2024 PIPE Warrants, as set forth in Post-Effective Amendment No. 3 to its Form F-1. The resale is by selling shareholders; the company will not receive proceeds from these resales.

The prospectus states there were 1,485,551 common shares outstanding as of June 15, 2026. The filing notes the January 2024 PIPE Warrants remain exercisable and that, if exercised for cash rather than on a cashless basis, the company could receive proceeds. The company reported a last sale price of $3.34 on Nasdaq on June 15, 2026.

Clearmind Medicine Inc. filed a Form 6-K furnishing its unaudited interim financial statements and MD&A for the three and six months ended April 30, 2026. The company reported a net loss of $2.0M for the quarter and $5.9M for the first half, driven by higher general and administrative and research expenses as it advances clinical trials.

Cash and cash equivalents were $11.4M as of April 30, 2026, with total assets of $14.5M and working capital of about $11.3M. Operating activities used $3.9M of cash in the six-month period, while equity financings and convertible promissory notes brought in significant funds.

Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $33.8M, ongoing losses, and dependence on additional debt or equity financing. During the period, an independent Data and Safety Monitoring Board issued multiple positive safety reviews for the Phase I/IIa CMND‑100 trial for Alcohol Use Disorder, allowing escalation to higher-dose cohorts. The company also completed reverse share splits and continues to carry sizable derivative warrant liabilities linked to prior financings.

HRT Financial LP, a ten percent owner of Clearmind Medicine Inc., reported mixed trading in the company’s common stock. On June 10, it executed an open-market purchase of 2,159,052 shares at $0.153 per share. On June 11, it made an open-market sale of 225,191 shares at $0.123 per share. After these transactions, HRT Financial LP directly held 1,838,075 shares of Clearmind Medicine common stock, indicating it was a net buyer over the two days.

Clearmind Medicine Inc. received an initial insider ownership report from institutional investor HRT Financial LP, which is identified as a ten percent owner. The Form 3 shows HRT Financial LP holding 101,951 shares of Common Stock directly, without reporting any recent purchases or sales.

Clearmind Medicine Inc. agreed to issue and sell additional convertible promissory notes with an aggregate principal amount of $1,000,000 to its CLA Investors under an existing facility of up to $10,000,000.

The buyers will pay cash equal to 90% of principal, or $900,000, for these notes. As part of the deal, the floor price used in the conversion price formula of the notes is being amended to $1.875 per common share. The transaction is expected to close on or about June 14, 2026 and is documented in an agreement dated June 12, 2026 that is filed as an exhibit.

Clearmind Medicine Inc. has agreed with its CLA Investors to issue and sell new convertible promissory notes. The notes have an aggregate principal amount of $1,500,000, with cash proceeds equal to 90% of principal, or $1,350,000, under previously amended securities purchase agreements allowing up to $10,000,000 in such notes.

Clearmind Medicine Inc. filed a Form 6-K highlighting a press release on the publication of a Japanese patent application for proprietary compositions containing 5-Methoxy-2-aminoindan (MEAI) to treat depression. This step adds to the company’s global intellectual property portfolio around its flagship non-hallucinogenic molecule.

Clearmind describes a large and growing market for anxiety and depression treatments and broader behavioral health. It notes about 3 million diagnosed cases of Major Depressive Disorder in Japan and outlines an MEAI-based pipeline that includes depression, alcohol use disorder, metabolic conditions such as weight loss, and other mental disorders. The company reports an intellectual property estate of nineteen patent families with 31 granted patents worldwide.

Clearmind Medicine Inc. filed a Form 6-K highlighting a key clinical step for its lead candidate CMND-100. Johns Hopkins Medicine’s Institutional Review Board has approved advancement of the ongoing Phase I/II trial, allowing the company to proceed to Parts B and C in healthy volunteers and Alcohol Use Disorder subjects. Management describes this as another step forward in CMND-100’s clinical development at a leading research institution. Clearmind is a clinical-stage biotech focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics and reports an intellectual property portfolio of nineteen patent families, including 31 granted patents.